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Received November 6, 2014; accepted January 21, 2015AbstractBackground: Ischemic preconditioning has been reported to protect the myocardium against ischemia and reperfusion injury. The underlying
mechanisms have been extensively investigated but are not fully elucidated. In this study, we investigated the role of apoptosis in ischemic
preconditioning protection and the signal pathways involved.
Methods: Myocardial ischemia and reperfusion were induced in anesthetized male SpragueeDawley rats by a 40-minute occlusion and a 3-hour
reperfusion of the left anterior descending coronary artery. Ischemic preconditioning was elicited by two 10-minute coronary artery occlusions
and two 10-minute reperfusions.
Results: The myocardial infarct size, expressed as the percentage of area at risk, was significantly decreased in the ischemic preconditioning
group (16.8 ± 2.0% and 27.9 ± 2.7% in the ischemia and reperfusion groups, respectively, p < 0.001). Additionally, ischemic preconditioning
significantly reduced apoptosis, as evidenced by the decrease in the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling-
positive nuclei, DNA laddering, and caspase-3 activation. Western blot analysis revealed that ischemic preconditioning significantly reduced
myocardial tumor necrosis factor-a levels. Bcl-2 was increased, whereas Bax was decreased in the myocardium. Phosphorylation of the pro-
survival kinases, including Akt and extracellular signal-regulated kinases 1 and 2, was significantly increased. Hemodynamics, area at risk, and
mortality did not differ significantly among the groups.
Conclusion: Ischemic preconditioning reduces apoptosis induced by myocardial ischemia and reperfusion. The underlying mechanisms might be
related to inhibition of both the extrinsic and the intrinsic apoptotic pathway via inhibition of production of tumor necrosis factor-a, modulation
of expression of Bcl-2 and Bax, and activation of the prosurvival kinases.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: apoptosis; ischemia and reperfusion injury; ischemic preconditioning; myocardial infarction; prosurvival kinasesConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Cheng-Hsiung Huang, Division of Cardiovas-
cular Surgery, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai
Road, Taipei 112, Taiwan, ROC.
E-mail address: chhuang@vghtpe.gov.tw (C.-H. Huang).
http://dx.doi.org/10.1016/j.jcma.2015.04.006
1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Ass1. Introduction
Ischemic preconditioning is a phenomenon in which brief,
reversible episodes of myocardial ischemia protect the
myocardium against subsequent prolonged ischemic insult.1
Such preconditioning protects the myocardium against
ischemia and reperfusion injury, by reduction of myocardialociation. All rights reserved.
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stunning,3 and attenuation of postischemic arrhythmia.4 It is a
universal phenomenon found in a variety of animals, such as
dogs,1 rats,5 rabbits,2,6 and pigs.3 This laboratory finding has
also been used to develop strategies to protect human
myocardium during cardiac surgery.7,8
The underlying mechanisms of ischemic preconditioning
have been extensively investigated. Activation of adenosine
receptors,9 protein kinase C,10 adenosine triphosphate-
sensitive potassium channels,11 and stretch-activated ion
channels plays an important role in the protective effects of
ischemic preconditioning.6,12 Inhibition of apoptosis has also
been reported to contribute to ischemic preconditioning pro-
tection.10,13 Myocardial ischemia and reperfusion produce
proinflammatory cytokines, such as tumor necrosis factor-a
(TNF-a), interleukin-1, and interleukin-6. TNF-a is capable of
inducing apoptosis via activation of the extrinsic apoptotic
pathway.14,15 Ischemic preconditioning has been shown to
protect the myocardium via inhibition of TNF-a release.16 In
addition, it has been reported to upregulate antiapoptotic Bcl-2
protein, downregulate proapoptotic Bax protein, and activate
the prosurvival kinases, including Akt and extracellular signal-
regulated kinase 1 and 2 (ERK1/2).17,18 Significantly reduced
apoptosis has also been found.18
Myocardial ischemia and reperfusion occur in acute MI and
cardiac surgery. These result in mortality, morbidity, pro-
longed hospital stays, and increased medical costs.19 In this
study, we investigated whether ischemic preconditioning re-
duces apoptosis induced by ischemia and reperfusion. The
roles of TNF-a, Bcl-2, Bax, and the prosurvival kinases,
including Akt and ERK1/2, were also examined. Our findings
might serve to elucidate the mechanisms through which
ischemic preconditioning protects the myocardium against
ischemia and reperfusion injury, and provide a rationale for the
development of therapeutic strategies to reduce myocardial
ischemia and reperfusion injury.
2. Methods
This study was approved by the Animal Experiment
Committee of Taipei Veterans General Hospital, Taipei,
Taiwan. Animals were treated humanely in accordance with
the “Guide for the Care and Use of Laboratory Animals”.402.1. Animal preparationThe techniques for animal preparation utilized in this study
have been reported previously.20 Briefly, male Spra-
gueeDawley rats (250e300 g) were anesthetized with intra-
peritoneal pentobarbiturate (40 mg/kg). After tracheotomy,
each rat was intubated and ventilated. The descending aorta
was cannulated for arterial pressure monitoring. Electrocar-
diography leads were placed on limbs. After median sternot-
omy, a 4-0 silk suture was passed around the proximal left
anterior descending coronary artery. The ends of the silk su-
ture were threaded through a small vinyl tube to form a snare.
The body temperature was monitored using a rectalthermometer and maintained at 37C with heating pads
throughout the experiments.2.2. Experimental protocolAfter achieving hemodynamic stability for 20 minutes, the
rats were divided randomly into three groups. Group 1 (the
sham group) received the same surgical procedures without
any pretreatment, coronary artery occlusion (CAO) or coro-
nary artery reperfusion. Group 2 (the ischemia and reperfusion
group) also did not receive any pretreatment. Group 3 (the
ischemic preconditioning group) received ischemic pre-
conditioning by two episodes of 10-minute CAO. Ten minutes
after the above treatments, rats in Groups 2 and 3 received a
40-minute CAO, which was induced by pulling of the snare
around the proximal left anterior descending coronary artery.
Successful occlusions were verified by observing the devel-
opment of ST-segment elevation and changes in the QRS
complex on the electrocardiograms and cyanotic changes in
the myocardium in the occluded area. After the 40-minute
CAO, the snare was released for reperfusion for 3 hours.
Reperfusion was confirmed by refilling the coronary artery and
visualizing a reactive hyperemic response. Arterial pressure,
heart rate, and electrocardiography were recorded simulta-
neously and continuously throughout the experiment.2.3. Determination of area at risk and MI sizeThe methods for determination of area at risk (AAR) and MI
size used in this study have been reported previously.21 Briefly,
2000 units of heparin were intravenously administered at the
end of the experiment. The heart was excised and placed on a
perfusion apparatus. The proximal left anterior descending
coronary artery was ligated at the site of the previous occlusion.
The ascending aorta was perfused with 1% Evans blue dye
(Sigma-Aldrich, St. Louis, MO, USA). The left ventricle plus
septum was cut into six to seven transverse slices, which were
incubated at 37C in 1% triphenyl tetrazolium chloride solution
for 20 minutes. The slices were weighed and fixed in 10%
formalin solution for 24 hours. The basal surfaces were photo-
graphed. Images were traced with a digitizer. The AAR and MI
area of each heart slice were calculated by planimetry. The
percentage of area of the AAR and MI in each heart slice was
multiplied by the weight of each slice. The total weight of the
AAR and MI was calculated and summed. The AAR was re-
ported as the percentage of the left ventricle plus septum, with
MI size reported as a percentage of the AAR.2.4. Terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling stainingAt the end of the experiments, the hearts were excised,
washed of blood, and sectioned at 3e4 mm. Tissue slides
were fixed in acetone. Endogenous peroxide activity was
quenched by incubation in 3% hydrogen peroxide in meth-
anol. Slides were rinsed with phosphate-buffered saline-
blocking solution and incubated with a permeabilization
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ples were incubated with terminal deoxynucleotidyl trans-
ferase and detection buffer conjugated with horseradish
peroxidase in a humid chamber at 37C for 60 minutes. A
diaminobenzidin chromogen (Boehringer, Mannheim, Ger-
many) was used. Counterstaining with hematoxylin was
performed. The number of terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL)-
positive myocyte nuclei was counted in randomly selected
areas and expressed as a percentage of the total number of
myocyte nuclei at a magnification of 200.2.5. DNA fragmentation using agarose gel
electrophoresisAt the end of the experiment, the hearts were excised,
washed of blood, frozen in liquid nitrogen, and ground to
powder. The powdered tissue, transferred to a 50-mL centri-
fuge tube with ~10 vol. extraction buffer [10mM Tris-HCl
(pH ¼ 8.0), 0.1M EDTA (pH ¼ 8.0), 0.5% sodium dodecyl
sulfate (SDS), and 20 mg/mL pancreatic RNAase], was incu-
bated and digested with proteinase K at 50C overnight. An
equal volume of phenol equilibrated with 1M Tris buffer
(pH ¼ 8.0) was added. After centrifugation at 5000g for 30
minutes at room temperature, the aqueous phase was trans-
ferred to a new 50-mL tube. The DNAwas precipitated by the
addition of 0.1 vol. 3M sodium acetate and 2 vol. 100%
ethanol. The concentration of DNA was measured by spec-
trophotometry (260 nm). Ten microgram of each sample of
DNA was electrophoretically fractionated on 2% agarose gel
with 0.5 mg/mL ethidium bromide. The DNA in the gel was
photographed under UV light. A qualitative analysis of DNA
fragmentation was performed by analyzing the pattern of low-
molecular-weight DNA (~180-bp multiples).2.6. Western blot analysis for activated caspase-3, TNF-
a, Bcl-2, Bax, Akt, and ERK1/2Table 1
Mortality rates and exclusions for the three groups.a
Group Treatment Number Mortality No. included
VF HF
1 Sham 18 0 0 18
2 I/R 27 0 1 26
3 IPC 27 0 1 26
HF ¼ heart failure; IPC ¼ ischemic preconditioning; I/R ¼ ischemia and
reperfusion; VF ¼ ventricular fibrillation.
a No significant differences in the mortality rate were observed among the
groups. Pearson's Chi-square p ¼ 0.710.At the end of the experiments, the hearts were excised,
washed of blood, and homogenized in buffer at 4C. After
centrifugation, protein concentrations were determined using a
modified Bradford assay. Equivalent amounts of protein sam-
pleswere loaded and separated on 15%SDS-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane.
After blocking with 5% nonfat dry milk in Tris-buffered saline
containing 0.1% Tween 20 (TBST), membranes were incubated
with anti-caspase-3, anti-TNF-a, anti-Bcl-2, anti-Bax, anti-Akt,
anti-phospho-Akt (Ser473), anti-ERK1/2, and anti-phospho-
ERK1/2 (Thr202/Thr204) antibodies [1:1000 (v/v) dilution] in
5% nonfat dry milk. The membranes were incubated in 5%
nonfat dry milk in TBST containing secondary antibody con-
jugated to horseradish peroxidase. Peroxidase activity was
visualized by an enhanced chemiluminescence substrate sys-
tem, followed by exposure to hyperfilms. b-Actin (1:2000
dilution) was detected as a loading control for protein quantity.
Optical density for each band was determined using NIH Image
1.6 and normalized against background density for each gel.2.7. Statistical analysisAll values were expressed as mean value ± standard devi-
ation. A computer program (SPSS 17.0; SPSS, Inc., Chicago,
IL, USA) was used for statistical analysis. Hemodynamic
variables were analyzed by a two-way analysis of variance
with repeated measures. Multiple comparisons of repeated
measures were tested by using within-subject contrasts. The
data were analyzed with the Student t test when comparing
means between two groups, or with one-way analysis of
variance and the Bonferroni post hoc multiple comparison test
when comparing multiple groups. Differences were considered
significant at p < 0.05.
3. Results3.1. Mortality and exclusionsSeventy-two rats were used in this study (Table 1). One rat
suffered from ventricular fibrillation and died. One rat died of
heart failure, which was defined as a progressive decrease of
systolic arterial pressure to <50 mmHg with global left ven-
tricular dilatation and poor contraction. These two rats were
excluded. The mortality rates for the three groups were not
significantly different ( p ¼ 0.710).3.2. Hemodynamic changes during the experimentsThe baseline mean arterial pressures and heart rates for the
three groups were not significantly different (Table 2).
Ischemic preconditioning did not cause any significant he-
modynamic changes. There were no significant changes in the
arterial pressures and heart rates throughout the experiments.
The hemodynamic variables were not significantly different
among the groups during the experiments.3.3. AAR and MI size analysisThe AAR values for the three groups, expressed as the
percentage of the left ventricle, were not significantly different
(49.4 ± 1.6% in Group 2 vs. 50.4 ± 3.0% in Group 3,
p ¼ 0.456; Fig. 1A). The MI size, expressed as a percentage of
AAR, was 27.9 ± 2.7% in Group 2. Ischemic preconditioning
significantly reduced the MI size in Group 3 (16.8 ± 2.0%,
p < 0.001; Fig. 1B).
Table 2
Hemodynamic changes during the experiments.a
Group Treatment Protocol Number Baseline 1 Baseline 2 CAO CAR
20 min 40 min 1 h 2 h 3 h
MAP (mmHg)
1 Sham 18 79 ± 9 80 ± 8 78 ± 9 75 ± 5 78 ± 7 76 ± 4 78 ± 6
2 I/R 26 80 ± 9 79 ± 10 73 ± 5 74 ± 8 75 ± 7 74 ± 4 74 ± 6
3 IPC 26 79 ± 11 77 ± 8 76 ± 6 78 ± 6 76 ± 11 75 ± 5 74 ± 6
HR (beats/min)
1 Sham 18 420 ± 42 435 ± 53 431 ± 39 426 ± 43 423 ± 43 424 ± 49 414 ± 55
2 I/R 26 431 ± 32 451 ± 49 443 ± 47 448 ± 34 439 ± 29 451 ± 34 433 ± 53
3 IPC 26 428 ± 45 418 ± 53 423 ± 37 433 ± 50 431 ± 49 425 ± 43 423 ± 46
PRP/1000 (mmHg*beats/min)
1 Sham 18 33.31 ± 5.14 34.80 ± 5.59 33.71 ± 4.84 32.00 ± 4.19 32.71 ± 4.24 32.34 ± 3.81 31.86 ± 3.11
2 I/R 26 34.61 ± 5.50 35.82 ± 7.34 32.48 ± 4.50 33.22 ± 5.76 33.07 ± 5.03 33.62 ± 3.91 32.31 ± 5.98
3 IPC 26 34.08 ± 6.59 32.39 ± 6.75 32.30 ± 4.13 33.88 ± 5.16 32.91 ± 6.33 31.78 ± 3.22 31.14 ± 4.01
Data are presented as mean ± standard deviation.
Baseline 1 ¼ baseline prior to ischemic preconditioning; Baseline 2 ¼ baseline after ischemic preconditioning; CAO¼ coronary artery occlusion; CAR ¼ coronary
artery reperfusion; HR ¼ heart rate; IPC ¼ ischemic preconditioning; I/R ¼ ischemia and reperfusion; MAP ¼ mean arterial pressure; PRP ¼ mean arterial
pressureeheart rate product.
a Rats in Group 1 did not receive any pretreatment, coronary artery occlusion, or reperfusion. The hemodynamic data shown for Group 1 were observed at the
same time points as those of the other two groups. There were no significant changes in MAP and HR throughout the experiments. There were no significant
differences in hemodynamic variables during the experiments.
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of apoptotic myocytes. The reaction product is dark brown.13
There were few stained nuclei in the myocardia of rats that
received the sham operation (Fig. 2A). Numerous nuclei in the
AAR of Group 2 rats contained the dark brown reaction
product, while only scattered nuclei in the AAR of Group 3
rats showed the dark brown reaction product. The TUNEL-
positive nuclei, expressed as the percentage of total nuclei,
were significantly increased in the AAR of Group 2, as
compared with their presence in the myocardia of Group 1 rats
(22.7 ± 3.3% vs. 0.8 ± 0.2%, p < 0.001; Fig. 2A). Ischemic
preconditioning significantly reduced the number of TUNEL-
positive nuclei (7.1 ± 1.5%, p < 0.001 vs. Group 2).Fig. 1. (A) Size of AAR, expressed as a percentage of the LV. (B) Size of MI, e
AAR ¼ area at risk; LV ¼ left ventricle; MI ¼ myocardial infarct.3.5. DNA fragmentation using agarose gel
electrophoresisConsistent with the findings of TUNEL staining, no DNA
fragmentation was detected in the myocardia of Group 1 rats
(Fig. 2B, lane 2). A clearly detected electrophoretic pattern
characterized by mononucleosomal and oligonucleosomal
DNA fragmentation (laddering) was found in the AAR of
Group 2 rats (Fig. 2B, lane 3). Little or no DNA laddering was
found in the AAR of Group 3 rats (Fig. 2B, lane 4).3.6. Assay of activated caspase-3Caspase-3 is constitutively expressed in cells as an inactive
precursor (32 kDa). The precursor is cleaved to an active p17xpressed as a percentage of the AAR. * p < 0.001 versus Group 2 (N ¼ 8).
Fig. 2. (A) Detection of DNA fragmentation in apoptotic cell nuclei in the myocardium using TUNEL staining. A representative photomicrograph is shown (200
magnification). Dark-brown staining (red arrowhead) indicates TUNEL-positive nuclei (upper panel). The percentage of TUNEL-positive nuclei in each group is
shown (lower panel). (B) Detection of DNA fragmentation in the myocardium using agarose gel electrophoresis. No DNA fragmentation was detected in the
myocardium of Group 1 rats (lane 2). DNA fragmentation was clearly detected in the area at risk of Group 2 rats (lane 3). Little or no DNA fragmentation was
found in the area at risk of Group 3 rats (lane 4). * p < 0.001 versus Group 1 (N ¼ 6). y p < 0.001 versus Group 2 (N ¼ 6). bp ¼ base pair; M ¼ molecular marker;
TUNEL ¼ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.
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analysis revealed that the band of activated caspase-3 was
faintly detectable in the myocardia of Group 1 rats (Fig. 3A,
lane 1). Myocardial ischemia and reperfusion significantly
increased the generation of activated caspase-3 in the AAR of
Group 2 rats, as evidenced by the increased density of the p17
subunit band ( p < 0.001 vs. Group 1; Fig. 3A, lane 2).
Ischemic preconditioning significantly reduced the increase of
activated caspase-3 in Group 3 rats ( p < 0.01 vs. Group 2;
Fig. 3A, lane 3).Fig. 3. (A) Caspase-3 activation assay. (B) TNF-a assay. Representative Western blo
activated caspase-3 and TNF-a band were analyzed by arbitrary units (lower pane
z p < 0.001 versus Group 2 (A) or Group 2-I (B) (N ¼ 4). x p < 0.01 versus Gro
TNF-a ¼ tumor necrosis factor-a.3.7. Assay of TNF-aTNF-a may induce apoptosis via activation of the extrinsic
apoptotic pathway.14,15 We analyzed the TNF-a production by
western blot analysis and found that myocardial ischemia and
reperfusion significantly increased TNF-a in the AAR of Group
2 rats, as demonstrated by the increased density of the TNF-a
band ( p < 0.001 vs. Group 1; Fig. 3B, lane 2). Ischemic pre-
conditioning significantly inhibited the increase of TNF-a in
Group 3 rats ( p < 0.01 vs. Group 2; Fig. 3B, lane 4).ts of activated caspase-3 and TNF-a are shown (upper panels). The densities of
ls). * p < 0.001 versus Group 1 (N ¼ 4). y p < 0.01 versus Group 1 (N ¼ 4).
up 2-I (N ¼ 4). I ¼ ischemic myocardium; NI ¼ nonischemic myocardium;
Fig. 4. (A) Bcl-2 assay. (B) Bax assay. Representative western blots of Bcl-2 and Bax are shown (upper panel). The densities of Bcl-2 and Bax bands were analyzed
by arbitrary units (lower panel). * p < 0.001 versus Group 1 (N ¼ 4). y p < 0.01 versus Group 1 (N ¼ 4). z p < 0.05 versus Group 1 (N ¼ 4). x p < 0.001 versus
Group 2-I (N ¼ 4). k p < 0.01 versus Group 2-I (N ¼ 4). ¶ p < 0.01 versus Group 2-NI (N ¼ 4). ** p < 0.01 versus Group 3-I (N ¼ 4). I ¼ ischemic myocardium;
NI ¼ nonischemic myocardium.
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reperfusion significantly decreased Bcl-2 in the AAR of Group
2 rats, as demonstrated by the attenuated densities of the Bcl-2
bands ( p < 0.05; Fig. 4A, lane 2). Ischemic preconditioning
significantly prevented the decrease of Bcl-2 in Group 3 rats
( p < 0.001 vs. Group 2; Fig. 4A, lane 4).
Compared with the sham group, myocardial ischemia and
reperfusion significantly increased the density of Bax bands in
the AAR of Group 2 rats ( p < 0.001; Fig. 4B, lane 2),Fig. 5. (A) Phospho-Akt and t-Akt assays. (B) Phosphoextracellular signal-regul
p-ERK, and t-ERK are shown (upper panel). The densities of p-Akt and p-ERK ban
(N ¼ 4). y p < 0.01 versus Group 1 (N ¼ 4). z p < 0.001 versus Group 2-I (N ¼ 4).
¶ p < 0.001 versus Group 3-I (N ¼ 4). I ¼ ischemic myocardium; NI ¼ nonischem
regulated kinases; t-Akt ¼ total Akt; t-ERK ¼ total extracellular signal-regulatedindicating increased tissue abundance of Bax. Ischemic pre-
conditioning significantly inhibited the increase of Bax in the
AAR of Group 3 rats ( p < 0.001 vs. Group 2; Fig. 4B, lane 4).3.9. Assay of Akt and ERK1/2Akt and ERK1/2 were activated by phosphorylation to
protect cells and inhibit apoptosis.17,18 Western blot analysis
showed that myocardial ischemia and reperfusion significantly
increased phospho-Akt in the AAR of Group 2 rats ( p < 0.01
vs. Group 1; Fig. 5A, lane 2). Ischemic preconditioning furtherated kinases and t-ERK assay. Representative western blots of p-Akt, t-Akt,
ds were analyzed by arbitrary units (lower panel). * p < 0.001 versus Group 1
x p < 0.01 versus Group 2-I (N ¼ 4). k p < 0.001 versus Group 2-NI (N ¼ 4).
ic myocardium; p-Akt ¼ phospho-Akt; p-ERK ¼ phosphoextracellular signal-
kinases.
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vs. Group 2; Fig. 5A, lane 4). The total Akt was not signifi-
cantly changed and was not significantly different among the
three groups.
Compared to the sham group, myocardial ischemia and
reperfusion did not significantly change the phospho-ERK1/2 in
the AAR of Group 2 rats ( p > 0.99 vs. Group 1; Fig. 5B, lane 2).
Ischemic preconditioning significantly increased the phospho-
ERK1/2 in the AAR of Group 3 rats ( p < 0.01 vs. Group 2;
Fig. 5B, lane 4). The total ERK1/2 was not significantly changed
and was not significantly different among the three groups.
4. Discussion
In the current study, we demonstrated that ischemic pre-
conditioning significantly reduced apoptosis in anesthetized
rats. Apoptosis and necrosis are two distinct forms of cell
death induced by ischemia and reperfusion. Ischemic pre-
conditioning has been reported to reduce MI size.1 Inhibition
of apoptosis has been shown to contribute to ischemic pre-
conditioning protection.10,13 Zhao et al23 reported that inhi-
bition of apoptosis was associated with reduction of necrosis.
Piot et al13 reported that ischemic preconditioning signifi-
cantly reduced MI size, DNA laddering, and TUNEL-stained
nuclei. They suggested that ischemic preconditioning might
limit irreversible injury by reducing apoptosis. There were no
significant hemodynamic changes during the experiments. The
reduction of apoptosis found in this study could not be
ascribed to hemodynamic changes. Although the underlying
mechanisms are not certain, we demonstrated that ischemic
preconditioning significantly reduced TNF-a, increased Bcl-2,
and decreased Bax. Phosphorylation of the prosurvivalFig. 6. Schematic presentation of the extrinsic (left) and intrinsic (right) pathwa
production of TNF-a and stimulation of TNF family death receptors. The activatio
leading to activation of caspase cascades. Ischemic preconditioning reduces apop
including Akt and ERK1/2, reduces apoptosis via modulation of expression of Bc
a ¼ tumor necrosis factor-a.kinases, including Akt and ERK1/2, was significantly
increased by ischemic preconditioning. Therefore, the under-
lying mechanism for reduction of apoptosis by ischemic pre-
conditioning might be related to inhibition of both the
extrinsic and the intrinsic apoptotic pathway via regulation of
the prosurvival and proapoptotic signals.
Activated caspase-3 is a universal effector of apoptosis.22
Activation of both the extrinsic and the intrinsic apoptotic
pathway results in cleavage of caspase-3, which activates the
execution phase of apoptosis.22,24,25 Yaoita et al26 reported
that administration of a caspase inhibitor significantly
decreased MI size and apoptosis. Piot et al27 demonstrated that
ischemic preconditioning attenuated caspase-3 activation.
They suggested that prevention of caspase activation contrib-
uted to myocardial protection.
It has been reported that TNF-a may bind with TNF-a
receptors and activate the extrinsic apoptotic pathway to
induce apoptosis.14,15 In this study, we demonstrated that
myocardial ischemia and reperfusion significantly increased
the TNF-a level in the myocardium, and ischemic pre-
conditioning limited the increase of TNF-a. Inhibition of
TNF-a release and apoptosis has been reported to protect the
myocardium against ischemia and reperfusion injury.16,28
Bcl-2 family proteins are important regulatory proteins of
the intrinsic apoptotic pathway. The ratio of antiapoptotic Bcl-
2 and proapoptotic Bax regulates the apoptotic pathways and
determines the death or survival of cells.24,25,29 Ischemic
preconditioning has been reported to protect the myocardium
by preventing the decrease of Bcl-2 and increase of Bax
induced by ischemia and reperfusion.24,30
Akt is a member of the prosurvival phosphatidylinositol-3
kinase pathway, which reduces apoptosis and leads to cellys of apoptosis. Myocardial ischemia and reperfusion induces apoptosis by
n of the Bcl-2 family causes release of cytochrome C from the mitochondria,
tosis via inhibition of TNF-a production. Activation of prosurvival kinases,
l-2 and Bax. ERK1/2 ¼ extracellular signal-regulated kinases 1 and 2; TNF-
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that ischemic preconditioning significantly increased phos-
phorylation of Akt and reduced MI size. The effects on
apoptosis, however, were not investigated in their study. The
Akt-involved pathways leading to antiapoptotic effects are
complex. Akt may phosphorylate the proapoptotic protein Bad
and prevent Bad from binding to antiapoptotic Bcl-2 and Bcl-
xL, releasing them for a prosurvival response.31 Additionally,
Akt may prevent apoptosis by inhibiting the activity of the
proapoptotic transcription factor p53.32,33
ERK1/2 are members of the mitogen-activated protein ki-
nases. It has been shown that activation of ERK1/2 by phos-
phorylation protects cells against necrosis and apoptosis.34
Activation of ERK1/2 plays a significant role in myocardial
protection. Hausenloy et al17 reported that ischemic pre-
conditioning significantly increased phosphorylation of ERK1/
2 and reduced MI size. Administration of an ERK1/2 inhibitor
significantly decreased the phosphorylation of ERK1/2 and the
limitation of MI size induced by ischemic preconditioning.
ERK1/2 activation has been reported to reduce apoptosis by
downregulating Bad and upregulating Bcl-2.35 Activation of
the prosurvival pathways involving Akt and ERK1/2 has been
demonstrated to reduce apoptosis by inhibiting the opening of
the mitochondrial permeability transition pore.36
In a report by Hausenloy et al,17 ischemic preconditioning
has been shown to significantly increase phosphorylation of
Akt and ERK1/2. MI size was significantly reduced. However,
the effects on apoptosis were not investigated in their study.
Lazou et al37 reported that ischemic preconditioning activated
ERK1/2 and attenuated apoptosis in rabbits. The role of Akt
was not determined in their study. In the current study, the
roles of both Akt and ERK1/2 were investigated. The pro-
tective effects of ischemic preconditioning on both reduction
of MI size and inhibition of apoptosis were observed. Addi-
tionally, we demonstrated that ischemic preconditioning
reduced TNF-a, Bcl-2, and Bax in the myocardium. The ef-
fects of ischemic preconditioning on both the extrinsic and the
intrinsic apoptotic pathway were seen in this study (Fig. 6).
Our study has limitations. MI size is affected by the size of
AAR and the extent of coronary collateral circulation. In the
current study, the sizes of the AAR, expressed as the percentage
of the left ventricle weight, were not significantly different
among the groups. No definite myocardial blood flow data were
collected in our study. However, rats have limited collateral
coronary circulation,38 and our model is comparable to that
widely used in experiments on myocardial ischemia and pre-
conditioning.5,10,13,26,27,33 TUNEL staining is a sensitive but not
a specificmethod for detection of apoptosis. DNA fragmentation
in the noncardiomyocytes might be stained. DNA fragmentation
on agarose gel electrophoresis is specific but not quantitative. In
this study, we conducted assays of caspase-3 activation, which
provide specific and quantitative analysis of apoptosis.39
In conclusion, our study demonstrated that ischemic pre-
conditioning reduced apoptosis. The underlying mechanisms
might be related to inhibition of both the extrinsic and the
intrinsic apoptotic pathway via inhibition of TNF-a produc-
tion, modulation of expression of Bcl-2 and Bax, andactivation of the prosurvival kinases, including Akt and ERK1/
2. Our findings disclose the protective effects and underlying
mechanisms of ischemic preconditioning. Further studies are
required to investigate other signal elements involved.
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